News

One year of treatment with Rinvoq (upadacitinib) reduced disease activity for most adults with non-radiographic axial spondyloarthritis (nr-axSpA) — an inflammatory condition related to ankylosing spondylitis (AS) — in a Phase 3 clinical trial. “These longer-term results continue to support the favorable benefit-risk profile of [Rinvoq] once daily…

Tapering off a TNF inhibitor — part of a class of medications that block pro-inflammatory molecules — may raise the risk of disease flare in people with spondyloarthritis, including among those with ankylosing spondylitis (AS), compared with staying on a standard dose, according to a review study. Further research…

Treatment with high doses of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with an increased risk of cardiovascular disease among adults with ankylosing spondylitis (AS), according to a Korean real-world study into NSAID dosing. Specifically, the risk was significantly higher for conditions such as heart attack, stroke, and congestive heart…

Women with axial spondyloarthritis (axSpA) or other inflammatory diseases maintained stable therapeutic levels of Cimzia (certolizumab pegol) throughout pregnancy, as announced by UCB, the therapy’s developer. The results, from the open-label Phase 1b CHERISH clinical trial (NCT04163016), were presented at the European Congress of Rheumatology held…

Machine learning and deep learning are already showing promise as tools to help diagnose and manage ankylosing spondylitis (AS), though the field is still in its infancy and more work must be done, a new review paper highlights. The paper, “Machine Learning and Deep Learning for…

Opioid use is highly prevalent among people in the U.S. with ankylosing spondylitis (AS), both before and after diagnosis, according to a medical claims database analysis. Similar results also were found among patients with other types of inflammatory diseases affecting the joints, such as psoriatic arthritis and rheumatoid arthritis,…

Sarcopenia, a gradual loss of muscle mass and strength, may happen at a rather young age in people with ankylosing spondylitis (AS), a systematic review study has found, with researchers suggesting AS patients should take action early to build muscle tissue and age healthier. While no specific age range…

Alvotech’s high-dose biosimilar of Humira (adalimumab) — a medication approved for ankylosing spondylitis (AS) and other inflammatory diseases — which was cleared by federal regulators earlier this year, will soon be launched in the U.S. under the brand name Simlandi. A biosimilar is a medication containing the…

Organizers of this year’s World AS Day, seek to raise awareness about the signs and symptoms of axial spondyloarthritis (axSpA), a disorder that’s thought to affect more than 50 million people globally. The day will be observed on Saturday, May 4. The campaign is coordinated by the…

Treatment with Taltz (ixekizumab) significantly eases spinal pain at night in adults with ankylosing spondylitis (AS) regardless of whether inflammation was well controlled with the therapy, according to new analyses from the Phase 3 COAST-V clinical trial. The study tested Taltz against either a placebo or adalimumab, which…